Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 20:27 IST

Avience Biomedicals Limited

NSE: AVIENCE · Medical Equipment & Supplies

Share price ₹263.85

up 4.93% · close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹145 Cr

P/E ratio

16.6

EPS FY to Mar 2026

P/B ratio

Pending

₹30 Cr IPO · by 23 Jun

ROCE

26.9%

ROE

32.3%

Dividend yield

0.0%

as of 20 Nov 2026

Profit checks5/7 clear

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Price
Loading AVIENCE data…

At a glance · Max

Every small chart follows the range above. Point at it to read a value; click it to open it.
Revenue (sales)
₹31.1 Cr
Sep 2026 · +16.07% on a year ago
Mar 2025 – Sep 2026 · 4 quarters
Operating margin
27.0%
average 27.7% · low 27.0% · high 29.9%
Mar 2025 – Sep 2026 · 4 quarters
Net profit
₹5.54 Cr
Sep 2026 · +22.03% on a year ago
Mar 2025 – Sep 2026 · 4 quarters
EPS (yearly)
₹21.71
FY26 · +23.28% on FY25
FY24 – FY26 · 3 years
Promoter holding
64.59%
FII 0.0% · DII 3.5%
Jun 2026 – Sep 2026 · 2 quarters

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit ₹5.54 Cr, up 22.0% on Sep 2025

Quarter to Sep 2026 · Consolidated · next results expected soon

Sales₹31.1 Crup 16.1% on Sep 2025
Operating profit₹8.39 Crup 15.7% on Sep 2025
Operating margin27.0%down 0.1 pts from 27.0%
Net profit₹5.54 Crup 22.0% on Sep 2025
Net margin17.8%up 0.9 pts from 16.9%
EPS₹10.10down 10.3% on Sep 2025
Sales, last 4 quarters ₹ crore
Show
Consolidated
Sales, operating profit and net profit, ₹ crore: 4 years to Mar 2026.
FY26Year to Mar 2026
Sales₹52.46 Cr
Operating profit₹15.10 Cr28.8% of sales
Net profit₹8.75 Cr16.7% of sales
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales.

Years to March, 2023–2026 · key lines

Yearly profit and loss, Years to March, 2023–2026
LineMar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26
Sales₹ crore10.9223.83change on a year before +118%44.92change on a year before +89%52.46change on a year before +17%
Operating profit₹ crore4.1811.52change on a year before +176%15.10change on a year before +31%
Operating margin% of sales17.54%25.65%28.78%
Other income₹ crore0.410.580.29
Net profit₹ crore2.167.10change on a year before +229%8.75change on a year before +23%
EPS₹ per share5.3617.61change on a year before +229%21.71change on a year before +23%

Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.

Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.

Sales

a year, compounded

3 years
69%
TTM
11%

Return on equity

average over the span

3 years
38%
Last year
32%

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 68.7% a year against a sector median of 19.7% — 49.0 percentage points faster.

AVIENCE68.7% a year
Sector median19.7% a year

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

How it compares with its peers

Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 1 of 11 on returns, 1 of 11 on margin.

Returns on capital1 of 11
Margin1 of 11

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 26.9% on capital, ahead of 91% of companies filed under the same label.

Return on capital26.9%
Ahead of91% of peers

Whether its growth pays for itself

No — Over the 3 years of cash statements on file it made ₹10 crore of cash from the business but spent ₹26 crore on plant and equipment, ₹16 crore more than it made; the gap was from lenders and shareholders.

Peers here are the 11 companies the exchange files under the same label (Medical Equipment & Supplies). That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

59 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

5 of 7 checks clear

2 of 9 checks could not be run.

Simple checks on the accounts. Which 2 are flagged is in Pro.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹145 Cr
Prev close
₹263.85
52w High
₹392
52w Low
₹225
Beta
—
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Valuation

P/E ratioEPS FY to Mar 2026
16.6
Industry P/E
42.7
P/B ratio₹30 Cr IPO · by 23 Jun
Pending
EV / EBITDA₹30 Cr IPO · by 23 Jun
Pending
Enterprise value₹30 Cr IPO · by 23 Jun
Pending
PEG ratio
—
Dividend yield
0.0%

Returns

ROCE
26.9%
ROCE 5y average
27.3%
ROE
32.3%
ROE 3y average
38.0%
ROE last year
32.0%
Return on assets
11.7%

Sales, profit & margins

Annual revenue
₹52.5 Cr
Annual profit
₹8.75 Cr
EPS
₹21.7
Operating margin
28.8%
Net profit margin
16.7%
EBITDA margin
28.8%
Sales latest quarterSep 2026 quarter
₹31.1 Cr
Profit latest quarterSep 2026 quarter
₹5.54 Cr
OPM latest quarterSep 2026 quarter
27.0%

Growth a year

Sales growth 3y
68.7%
Sales growth 5y
—
Sales growth TTM
11.0%
Profit growth 3y
—
Profit growth 5y
—
Profit growth TTM
—
YoY quarterly sales growthSep 2026 vs Sep 2025
16.1%
YoY quarterly profit growthSep 2026 vs Sep 2025
22.0%

Balance sheet

Book Value
Pending
Face Value
₹10.0
Borrowings
₹28.9 Cr
Total debt
₹27.2 Cr
Total cash
₹5.73 Cr
Debt / Equity
0.4
Interest coverage
8.3
Reserves / Equity
6.8

Cash & payout

Operating cash flow
₹5.91 Cr
Free cash flow
-₹7.44 Cr
FCF yield
-6.3%
Net cash flow
-₹1.95 Cr
Dividend payout
0.0%

Holdings

Promoter holding
64.6%
FII holding
0.0%
DII holding
3.5%
Public holding
31.9%

A newly listed company shows “Pending” until it files a balance sheet after its IPO: the last one is from before the issue, so the IPO money would be counted twice.

Peers

Peers
CompanyPrice ₹P/EMkt cap ₹ CrDiv yieldProfit qtr ₹ CrProfit changeSales qtr ₹ CrSales changeROCE
Molbio Diagnostics Limited1,495.50111.417,2340.00%7.70-92.79%259-55.36%19.31%
Poly Medicure Limited1,635.7052.516,5800.21%95.1+3.40%581+30.78%14.20%
Sahajanand Medical Technologies Limited527.6081.35,3640.00%26.5+26.04%373+24.89%11.42%
Tarsons Products Limited303.40197.31,6140.00%-0.34-110.24%124+20.83%4.56%
Fischer Medical Ventures Limited22.331,5600.21%0.80-94.19%107+24.48%11.58%
Laxmi Dental Limited187.5727.01,0320.00%10.0+11.51%79.5+10.03%15.17%
Fabtech Technologies Limited140.3720.96240.44%15.0-46.34%92.1-24.20%14.00%
Avience Biomedicals Limited263.8516.61450.00%5.54+22.03%31.1+16.07%26.95%
Medianof the whole group of 11, 20 Nov 202643.30.00%-31.89%+17.50%13.99%

Median: the middle value of the whole peer group of 11 companies. Price and rupee sizes are left blank there, as a middle value of those says little.

Competes with 7 listed companies

Fabtech Technologies Limited, Fischer Medical Ventures Limited, Laxmi Dental Limited, Molbio Diagnostics Limited, Poly Medicure Limited, Sahajanand Medical Technologies Limited, Tarsons Products Limited

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Consolidated

At Mar 2026: ₹74.5 cr of assets, and who funds them

Shareholders’ own money funds 42% of it; borrowings 39%.

What it owns

  • Fixed assets ₹16.1 cr 22%
  • Being built ₹12.9 cr 17%
  • Investments ₹0.03 cr 0%
  • Everything else ₹45.6 cr 61%

Who funds it

  • Shareholders’ money ₹31.4 cr 42%
  • Borrowings ₹28.9 cr 39%
  • Everything else ₹14.2 cr 19%

Each year end. Newest year end shaded.

Balance sheet
Line, ₹ croreMar 2024FY24Mar 2025FY25Mar 2026FY26
Equity capital3.284.034.03
Reserves2.9418.6327.38
Borrowings15.1322.1628.93
Other liabilities13.1811.6014.20
Total funding34.5356.4274.54
Fixed assets10.2513.1016.06
Being built (CWIP)0.034.6212.85
Investments0.030.030.03
Other assetsreceivables, cash, rest24.2238.6745.60
Total assets34.5356.4274.54

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Consolidated

Pick a period to see where its cash went.

Where the cash went, year to Mar 2026, ₹ crore

In words

  • The business brought in ₹5.91 cr, 39% of its operating profit before tax.
  • It put ₹13.3 cr into assets and investments.
  • It raised ₹5.42 cr from shareholders and lenders.
  • Cash in hand fell by ₹1.95 cr. Free cash flow: −₹7.44 cr.
Cash flow
Line, ₹ croreMar 2024FY24Mar 2025FY25Mar 2026FY26
From the business1.023.395.91
From investing-3.90-9.54-13.27
From financingdividends, buybacks, loans2.9310.215.42
Net change in cash0.054.06-1.95
Free cash flow-2.81-5.87-7.44
Cash ÷ operating profitbefore tax24.00%29.00%39.00%

Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.

Efficiency ratios

How fast customers pay and how well capital earns. Each year, Mar 2024 to Mar 2026.

Consolidated

Debtor days

146 days

Days customers take to pay. Lower is faster.

146 days in FY26, against 140 days in FY25. Over these 3 years: 124 days (FY24) to 146 days (FY26).

Inventory days

217.5 days

Days stock sits before it is sold.

217.5 days in FY26, against 176.3 days in FY25. Over these 3 years: 176.3 days (FY25) to 290.3 days (FY24).

Days payable

119.9 days

Days it takes to pay its suppliers.

119.9 days in FY26, against 98.1 days in FY25. Over these 3 years: 98.1 days (FY25) to 129.9 days (FY24).

Cash conversion cycle

243.9 days

Debtor days plus inventory days, less days payable.

243.9 days in FY26, against 218.1 days in FY25. Over these 3 years: 218.1 days (FY25) to 284.3 days (FY24).

Working capital days

74.1 days

Days of sales tied up in running the business.

74.1 days in FY26, against 70.3 days in FY25. Over these 3 years: 28.6 days (FY24) to 74.1 days (FY26).

Return on capital (ROCE)

27.0%

Operating profit on the capital used.

27.0% in FY26, against 34.2% in FY25. Over these 2 years: 27.0% (FY26) to 34.2% (FY25).

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To 30 Sep 2026

Share of the company held by each group, at each filed quarter end, Jun 2026 to Sep 2026.

Promoters

The group that controls the company

64.59%

Since Jun 2026 no change

Foreign funds (FIIs)

Investors outside India

0.03%

Since Jun 2026 −3.03 pts

Indian funds (DIIs)

Mutual funds, insurers, banks

3.48%

Since Jun 2026 −5.60 pts

Public

Individuals and others

31.89%

Since Jun 2026 +8.63 pts

Number of shareholders

Accounts holding the share

719

Since Jun 2026 +89

  • Foreign funds cut their share from 3.06% to 0.03%; Indian funds cut theirs from 9.08% to 3.48%.
  • Promoters held 64.59% in every quarter from Jun 2026 to Sep 2026.
  • Shareholders grew from 630 to 719.
Shareholding, % of the company at each quarter end
Holder, %Jun 2026Sep 2026Change
Promoters64.5964.590.00
Foreign funds (FIIs)3.060.03−3.03
Indian funds (DIIs)9.083.48−5.60
Public23.2631.89+8.63
Shareholders630719+89

A figure in bold moved by 0.5 points or more from the quarter before. Change = Sep 2026 against Jun 2026, in points.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividend a share, by the year of its ex-date

No dividend on record.

Share of profit paid as dividend

No dividend payout is filed for this company.

Splits, bonuses & buybacks

None on record.

Big trades by funds and insiders

  • SURESH ZUNZUNWALAbulk deal, NSEBought 42,000 · at ₹245.3820 Jul 2026
  • SURESH ZUNZUNWALAbulk deal, NSESold 42,000 · at ₹265.5520 Jul 2026
  • MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDbulk deal, NSEBought 90,000 · at ₹321.203 Jul 2026
  • GINNI FINANCE PRIVATE LIMITEDbulk deal, NSEBought 31,800 · at ₹321.213 Jul 2026
  • NEO APEX SHARE BROKING SERVICES LLPbulk deal, NSESold 29,400 · at ₹321.483 Jul 2026
  • GREEN PEAKS ENTERPRISES LLPbulk deal, NSESold 42,000 · at ₹394.2529 Jun 2026
  • NIRAJ RAJNIKANT SHAHbulk deal, NSEBought 98,400 · at ₹395.2025 Jun 2026
  • NEO APEX SHARE BROKING SERVICES LLPbulk deal, NSEBought 50,400 · at ₹414.9525 Jun 2026
  • GREEN PEAKS ENTERPRISES LLPbulk deal, NSEBought 48,600 · at ₹414.9525 Jun 2026
  • KIFS ENTERPRISEbulk deal, NSEBought 30,000 · at ₹395.2025 Jun 2026

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Healthcare
Industry
Medical Equipment & Supplies
Symbol
AVIENCE
ISIN
INE0V9I01017
Part of
  • Nifty SME Emerge

Sites · 2

  • Manufacturing Unit 1Noida, Uttar Pradesh
  • New manufacturing unit at Plot No. 70, Sector 28, Medical Device Park, YEIDAGautam Buddha Nagar, Uttar Pradesh

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Revenue and margin

  • EBIT marginSep 2026 quarter24.41%

Profit quality

  • Other income shareSep 2026 quarter6.92%
  • Interest coverSep 2026 quarter13.31x

Growth

  • Revenue growth (YoY)Sep 2026 quarter16.07%

Capex

  • CapexFY to Mar 2026₹13.4 Cr
  • Capex to revenueFY to Mar 202625.45%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Sep 2624.41%Computed from the filings
Jun 26—not filed
Mar 2627.36%Computed from the filings
Dec 25—not filed

Other income share · quarterly

Source: Computed from the filings

Sep 266.92%Computed from the filings
Jun 26—not filed
Mar 263.61%Computed from the filings
Dec 25—not filed

Interest cover · quarterly

Source: Computed from the filings

Sep 2613.31xComputed from the filings
Jun 26—not filed
Mar 268.16xComputed from the filings
Dec 25—not filed

Revenue growth (YoY) · quarterly

Source: Computed from the filings

Sep 2616.07%Computed from the filings
Jun 26—not filed
Mar 264.99%Computed from the filings

Capex (fiscal year) · yearly

Source: Computed from the filings

FY26₹13.4 CrComputed from the filings
FY25₹9.26 CrComputed from the filings
FY24₹3.83 CrComputed from the filings

Capex to revenue (fiscal year) · yearly

Source: Computed from the filings

FY2625.45%Computed from the filings
FY2520.61%Computed from the filings
FY2416.07%Computed from the filings

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Avience Biomedicals Limited through this map.

Buys from · 1

  • Mindray Medical India PrivateTrading goods (advanced IVD solutions)

Competes with · 7 companies

Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.

8 · News & documents

News and what it reaches

Filings and news about Avience Biomedicals Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

No recent news or filings for this company.

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.